Sei Investments Co. Has $902,000 Stock Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX)

Sei Investments Co. decreased its position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 67.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 29,969 shares of the biopharmaceutical company's stock after selling 61,471 shares during the period. Sei Investments Co.'s holdings in TG Therapeutics were worth $902,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. 1620 Investment Advisors Inc. acquired a new stake in shares of TG Therapeutics during the fourth quarter worth approximately $128,000. Teacher Retirement System of Texas grew its holdings in TG Therapeutics by 18.3% during the 4th quarter. Teacher Retirement System of Texas now owns 43,565 shares of the biopharmaceutical company's stock worth $1,311,000 after acquiring an additional 6,742 shares in the last quarter. Xponance Inc. increased its position in shares of TG Therapeutics by 14.7% in the 4th quarter. Xponance Inc. now owns 10,318 shares of the biopharmaceutical company's stock worth $311,000 after purchasing an additional 1,326 shares during the last quarter. Cibc World Markets Corp acquired a new stake in shares of TG Therapeutics in the 4th quarter valued at about $393,000. Finally, GWN Securities Inc. bought a new position in shares of TG Therapeutics during the fourth quarter worth about $395,000. Institutional investors and hedge funds own 58.58% of the company's stock.

TG Therapeutics Price Performance

Shares of TGTX stock traded up $0.73 during mid-day trading on Friday, hitting $36.71. 2,052,937 shares of the stock traded hands, compared to its average volume of 3,107,506. The company has a debt-to-equity ratio of 1.27, a quick ratio of 3.91 and a current ratio of 4.59. The firm has a market cap of $5.77 billion, a price-to-earnings ratio of -367.06 and a beta of 2.14. The company's 50-day simple moving average is $35.76 and its 200-day simple moving average is $31.44. TG Therapeutics, Inc. has a twelve month low of $12.93 and a twelve month high of $43.32.

Remove Ads

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last issued its quarterly earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.15 EPS for the quarter, topping the consensus estimate of $0.08 by $0.07. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. The firm had revenue of $108.19 million for the quarter, compared to analysts' expectations of $100.67 million. As a group, equities research analysts expect that TG Therapeutics, Inc. will post 0.08 earnings per share for the current year.

Analysts Set New Price Targets

Several brokerages recently weighed in on TGTX. StockNews.com raised TG Therapeutics from a "sell" rating to a "hold" rating in a report on Tuesday, March 4th. HC Wainwright restated a "buy" rating and set a $55.00 price objective on shares of TG Therapeutics in a research note on Tuesday, March 4th. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $40.67.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.